| ||||||||||||||||||||||
| ||||||||||||||||||||||
Entries tagged "Pfizer"Bristol-Myers looking to swallow Elan in piecesRumors of Bristol-Myers Squibb interest in the auction of Irish biotech Elan sent shares up in London trading. Evercore hires BlackRock co-founder as CEOEvercore brings in BlackRock co-founder Ralph Schlosstein as president and chief executive. Video: Louis Capital's van Batenburg on Pfizer-Wyeth obstaclesIn this edition of Inside the Deal, Robbert van Batenburg, head of equity research for Louis Capital Markets, tells Suzanne Stevens that the stakes for both companies are high. Sanofi chief thinks smallerFrench drug firm Sanofi-Aventis SA probably won't make a massive acquisition to boost its flagging product pipeline. Snoozer on the Street as bailout delayedPresident Obama hit the snooze button on Monday, delaying announcement of the bank rescue plan until Tuesday, and Wall Street did just that -- snoozed. Here comes pharma's 'me-too' mergersThe pharmaceutical industry is notorious for creating copycat drugs. Now Pfizer's $68 billion bid for Wyeth could prompt Merck, Sanofi-Aventis and other peers to launch 'me-too' mergers. Wyeth's kill fee, and much much morePfizer Inc. and Wyeth just released their merger agreement, and there are plenty of details to chew over. We'll pass them along as we read through the document. ... Bayer has healthy appetite for more acquisitionsBayer AG's CEO Arthur Higgins told The Wall Street Journal the healthcare company may swallow up some smaller healthcare businesses in the next six to 24 months. No surprise given its acquisition pace so far this year, but Higgins told the Journal that the company is interested in acquiring businesses that make over-the-counter drugs, medications for animals and medical devices, which would be a divergence from its recent deals. ... Rabble Babble: ImClone's mystery bidder to reveal itself this weekImClone Systems Inc. said a mystery bidder, which has tentatively offered a bid of $70 a share or $6.1 billion, has informed the company that it will either make a formal bid or withdraw from talks by the end of the day on Wednesday. ... Bayer bid a rumor, Pfizer woes not a rumorIndiplon. Exubera. Dalbavancin. Torcetrapib. Chantix. Quick quiz: What do these names have in common? No, they're not rap stars or distant planets. They're all high-profile drugs from New York's Pfizer Inc. that have tanked or run into big problems the past couple years. The antibiotic dalbavancin, aimed at nasty super-resistant bugs like MRSA, was in line for regulatory approval when Pfizer said Tuesday it would have to put it through more testing.Pfizer's poor track record of late was the backdrop to unfounded rumors Tuesday morning that it was mulling a takeover bid of Germany's Bayer AG. Investors reacted by driving... Could Bayer be taken over by Pfizer?Takeover rumors of Bayer AG by New York-based Pfizer Inc. boosted shares of the German drugs and chemicals group Tuesday morning. ... Ranbaxy still in play?Japanese drug firm Daiichi Sankyo Co. Ltd. made waves two days ago with its intent to buy a majority of Indian generics firm Ranbaxy Laboratories Ltd. for as much as $4.6 billion. But now, the Indian press suggests others might step in with offers. ... Top tagsYou have executed a tag search on Dealscape. On the left,you will find a comprehensive list of stories tagged "Pfizer." Below are the most-popular tags for Dealscape. On the right of the page you will find a search box to dig deeper into our content.
 Deal Video
    Community
 Elsewhere on The Deal.comDealwatch
The Deal MagazineCorporate Dealmaker
The Deal VideoCategories
Blog roll
Archives
| ||||||||||||||||||||||
| ||||||||||||||||||||||
